Bone Morphogenetic Protein-2 and Osteopontin Gene Expression in Epicardial Adipose Tissue from Patients with Coronary Artery Disease Is Associated with the Presence of Calcified Atherosclerotic Plaques

It has been proposed that the cardiovascular effects of obesity are related to epicardial adipose tissue (EAT), which seems to play an active role on the development and calcification of atherosclerotic plaques, but the mechanisms are still unknown. Therefore, the aim of this study was to determine whether the EAT expresses the genes of calcifying factors and whether such expression is associated with the body mass index (BMI) and with the presence of coronary artery calcium (CAC) in patients with coronary artery disease (CAD). Forty-three patients with CAD were enrolled specifically for this study, and their CAC score and EAT volume were determined by computed tomography. As the group of comparison, 41 patients with aortic valve stenosis and CAC = 0 were included (control group). A representative subgroup of 16 CAD patients and 23 controls were selected to obtain EAT biopsies during the chirurgical procedure from the atrio-interventricular groove. The mRNA expression of bone morphogenetic protein-2 and -4 ( , osteopontin ( ), osteonectin ( ), and osteoprotegerin ( ) in EAT was determined by qPCR. The gene expression of and was 70% and 52% higher in the EAT from CAD patients than that in controls, respectively, whereas the expression of , and was similar in both groups. The EAT volume positively correlated with and with the BMI, suggesting a relationship of obesity with local higher expression of calcifying genes in the coronary territory. The logistic regression analysis showed that high levels of both and increased about 6 and 8 times the odds of coronary calcification (CAC score > 0), respectively. EAT correlated with BMI and expressed the mRNA of calcifying genes but only and expression was higher in CAD patients. Higher levels of both and statistically determined the presence of calcium in coronary arteries of CAD patients.